₹943.7 36.3 4.0%
Last Trade - 09/04/21
| Market Cap | £5.40bn |
| Enterprise Value | £5.56bn |
| Revenue | £2.43bn |
| Position in Universe | 78th / 3106 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 121,205 | 139,552 | 150,899 | 164,998 | 195,636 | 230,985 | 251,391 | 264,972 | +13.8% | ||
| +34.9 | +27.7 | +13.5 | +5.5 | +0.5 | +17.6 | +25.8 | -2.29 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.
| Last Annual | March 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | December 26, 1986 |
| Public Since | January 19, 1995 |
| No. of Shareholders: | 212,246 |
| No. of Employees: | 18,469 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | S&P BSE 100 , |
| Exchange | National Stock Exchange of India |
| Shares in Issue | 585,938,609 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Water Mark Building Plot No 11,Survey no9 Kondapur Hitech City, HyderabadTelangana, HYDERABAD, 500084, India |
| Web | https://www.aurobindo.com/ |
| Phone | +91 40 66725000 |
| Contact | Krishna Kiran (IR Contact Officer) |
| Auditors | BSR & Associates LLP |
As of 09/04/21, shares in Aurobindo Pharma are trading at ₹943.7, giving the company a market capitalisation of £5.40bn. This share price information is delayed by 15 minutes.
Shares in Aurobindo Pharma are currently trading at ₹943.7 and the price has moved by 0.105k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aurobindo Pharma price has moved by 25.33% over the past year.
Of the analysts with advisory recommendations for Aurobindo Pharma, there are there are currently 16 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aurobindo Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aurobindo Pharma is scheduled to issue upcoming financial results on the following dates:
The Aurobindo Pharma dividend yield is 0.61% based on the trailing twelve month period.
Last year, Aurobindo Pharma paid a total dividend of 5.75, and it currently has a trailing dividend yield of 0.61%. Looking ahead, Aurobindo Pharma has not announced an ex-dividend date yet.
Aurobindo Pharma has yet to annouce their ex-dividend date. The historic dividend yield on Aurobindo Pharma shares is currently 0.61%.
To buy shares in Aurobindo Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Aurobindo Pharma are currently trading at ₹943.7, giving the company a market capitalisation of £5.40bn.
Here are the trading details for Aurobindo Pharma:
Based on an overall assessment of its quality, value and momentum, Aurobindo Pharma is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Aurobindo Pharma are currently priced at ₹943.7. At that level they are trading at 13.38% discount to the analyst consensus target price of 0.00.
Analysts covering Aurobindo Pharma currently have a consensus Earnings Per Share (EPS) forecast of 61.823 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aurobindo Pharma. Over the past six months, the relative strength of its shares against the market has been -10.23%. At the current price of ₹943.7, shares in Aurobindo Pharma are trading at 10.15% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Aurobindo Pharma PE ratio based on its reported earnings over the past 12 months is 16.94. The shares are currently trading at ₹943.7.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Aurobindo Pharma's management team is headed by:
Here are the top five shareholders of Aurobindo Pharma based on the size of their shareholding:
